The article discusses the future of psychopharmacologic treatment of depression as of August 2010. The author states that as of the said date, limitations in pharmacotherapies of depression include the fact that they are monoamine-based, they have modest efficacy and they have significant tolerability issues. There are a number of drug mechanisms approved either in the U.S. or Europe that may represent the future of psychopharmacology of depression including multimodal serotonergic agents, glutamatergic treatments and triple uptake inhibitors.